INTERNAL DOCUMENT — CONFIDENTIAL
Respiratory Market Entry Strategy 2025

1. Market Overview
The global respiratory therapeutics market is valued at $55.2 billion (2024) and projected to reach $78.5 billion by 2030 (CAGR 6.0%).

Key segments:
- Asthma: $25.3B — dominated by biologics (Dupixent, Nucala, Fasenra)
- COPD: $18.7B — triple therapy era (Trelegy, Breztri)
- Idiopathic Pulmonary Fibrosis (IPF): $5.8B — high unmet need
- Cystic Fibrosis: $5.1B — Trikafta dominance by Vertex

2. Repurposing Opportunity Assessment

A. Metformin for COPD
Evidence level: Moderate (5 observational studies, 2 pilot RCTs)
Mechanism: Anti-inflammatory effects via AMPK activation; reduction in airway remodeling
Key publications:
- Hitchings et al., Lancet Respir Med 2021: pilot RCT showed 25% reduction in exacerbations
- Polverino et al., Am J Respir Crit Care Med 2023: metformin reduced inflammatory markers (IL-6, TNF-α) in COPD patients with comorbid diabetes
Market opportunity: Estimated $2.1B for COPD patients with metabolic comorbidities
Competitor landscape: Low — no major pharma pursuing this approach
Unmet need score: 72/100
Recommendation: STRONG — initiate Phase 2 clinical trial targeting COPD patients with metabolic syndrome

B. Losartan for Pulmonary Fibrosis
Evidence level: Low-Moderate (preclinical + case series)
Mechanism: TGF-β signaling inhibition via AT1 receptor blockade; reduction in collagen deposition
Preclinical data: 40% reduction in lung fibrosis score in bleomycin mouse model
Market opportunity: $1.5B — IPF patients who fail or cannot tolerate nintedanib/pirfenidone
Current SOC limitations: Nintedanib causes diarrhea (62%); pirfenidone causes photosensitivity (42%) and GI effects
Advantage: Losartan has decades of safety data, costs <$30/month
Unmet need score: 85/100
Recommendation: MODERATE — need Phase 2 proof-of-concept before significant investment

C. Sildenafil for Pulmonary Arterial Hypertension (already approved — extension)
Current status: Revatio approved for PAH Group 1
Opportunity: PAH Group 3 (associated with lung disease) — growing unmet need
Market expansion: Additional $800M opportunity if Group 3 indication secured
Recommendation: Discuss sNDA pathway with regulatory affairs

3. Regional Strategy
- India: Priority market for COPD repurposing (high disease burden, price-sensitive market, strong API manufacturing base)
- US/EU: Premium pricing for IPF indication
- Japan: Respiratory biologics market growing 12% annually — partnership opportunity

4. Competitive Intelligence
Key watch-list companies:
- Boehringer Ingelheim: Dominant in IPF (nintedanib); expanding to ILD
- AstraZeneca: Tezepelumab for severe asthma; COPD biologics pipeline
- GSK: Nucala lifecycle management; inhaler portfolio restructuring
- Sanofi/Regeneron: Dupixent expansion into COPD

5. Next Steps
Q1 2025: Complete feasibility study for metformin-COPD trial
Q2 2025: Seek academic partnerships for losartan-IPF proof-of-concept
Q3 2025: Submit IND if metformin-COPD data supports progression
